APA (7th ed.) Citation

3rd, C. H., JL, C., C, V. L., A, F., M, Y., DE, D., . . . PR, G. (2020). Response to "letter concerning: Clewell (2019) incorporation of in vitro metabolism data and physiologically based pharmacokinetic modeling in a risk assessment for chloroprene." (UIHT-2020-0053). Inhalation toxicology, 32(9-10), 369. https://doi.org/10.1080/08958378.2020.1817199

Chicago Style (17th ed.) Citation

3rd, Clewell HJ, Campbell JL, Van Landingham C, Franzen A, Yoon M, Dodd DE, Andersen ME, and Gentry PR. "Response to "Letter Concerning: Clewell (2019) Incorporation of In vitro Metabolism Data and Physiologically Based Pharmacokinetic Modeling in a Risk Assessment for Chloroprene." (UIHT-2020-0053)." Inhalation Toxicology 32, no. 9-10 (2020): 369. https://doi.org/10.1080/08958378.2020.1817199.

MLA (9th ed.) Citation

3rd, Clewell HJ, et al. "Response to "Letter Concerning: Clewell (2019) Incorporation of In vitro Metabolism Data and Physiologically Based Pharmacokinetic Modeling in a Risk Assessment for Chloroprene." (UIHT-2020-0053)." Inhalation Toxicology, vol. 32, no. 9-10, 2020, p. 369, https://doi.org/10.1080/08958378.2020.1817199.